Amygdala TDP-43 pathology is associated with behavioural dysfunction and ferritin accumulation in amyotrophic lateral sclerosis
Preprint
Abstract
Background: Cognitive and behavioural symptoms associated with amyotrophic lateral sclerosis and frontotemporal spectrum disorders (ALSFTSD) are thought to be driven, at least in part, by the pathological accumulation of TDP-43. Methods: Here we examine post-mortem tissue from six brain regions associated with cognitive and behavioural symptoms in a cohort of 30 people with sporadic ALS (sALS), a proportion of which underwent standardized neuropsychological behavioural assessment as part of the Edinburgh Cognitive ALS Screen (ECAS). Results: Overall, the behavioural screen performed as part of the ECAS predicted accumulation of pathological phosphorylated TDP-43 (pTDP-43) with 100% specificity and 86% sensitivity in behaviour-associated brain regions. Notably, of these regions, pathology in the amygdala was the most predictive correlate of behavioural dysfunction in sALS. In the amygdala of sALS patients, we show variation in morphology, cell type predominance, and severity of pTDP-43 pathology. Further, we demonstrate that the presence and severity of intra-neuronal pTDP-43 pathology, but not astroglial pathology, or phosphorylated Tau pathology, is associated with behavioural dysfunction. Cases were also evaluated using a TDP-43 aptamer (TDP-43 APT ), which revealed that pathology was not only associated with behavioural symptoms, but also with ferritin levels, a measure of brain iron. Conclusions: Intra-neuronal pTDP-43 and cytoplasmic TDP-43 APT pathology in the amygdala is associated with behavioural symptoms in sALS. TDP-43 APT staining intensity is also associated with increased ferritin, regardless of behavioural phenotype, suggesting that ferritin increases may occur upstream of clinical manifestation, in line with early TDP-43 APT pathology, representing a potential region-specific imaging biomarker of early disease in ALS. Key Messages: What is already known on this topic: The amygdala is a key brain region in regulating behavior and emotional cognition and has been shown recently, through imaging studies, to be affected in ALS and FTD patients. What this study adds: Here we examine the underlying pathology driving the association between the amygdala and behavioural symptoms in sporadic ALS demonstrating that region specific TDP-43 pathology and brain iron accumulation could represent potential early biomarkers of dysfunction. How this study might affect research, practice, or policy: The correlation between early TDP-43 pathology (detected by RNA aptamer) and increased ferritin (brain iron accumulation) occurring upstream of clinical manifestation represents a potential, region-specific (amygdala), early imaging biomarker in ALS. This means that people at risk could be identified early and stratified for clinical trials prior to substantial neuronal cell loss and symptom onset.Keywords
All Related Versions
- Published version: Brain Communications, 8 (2).
This publication has 41 references indexed in Scilit:
- RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALSActa Neuropathologica, 2024
- Combining structural and metabolic markers in a quantitative MRI study of motor neuron diseasesAnnals of Clinical and Translational Neurology, 2021
- Cognitive phenotypes of sequential staging in amyotrophic lateral sclerosisCortex, 2018
- Electrochemical studies of tau protein-iron interactions—Potential implications for Alzheimer’s DiseaseElectrochimica Acta, 2017
- Edinburgh Cognitive and Behavioural ALS Screen (ECAS)-Italian version: regression based norms and equivalent scoresNeurological Sciences, 2017
- Iron Oxides in the Human Brain2016
- Susceptibility-weighted imaging and quantitative susceptibility mapping in the brainJournal of Magnetic Resonance Imaging, 2014
- Increased serum ferritin levels in amyotrophic lateral sclerosis (ALS) patientsJournal of Neurology, 2008
- Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosisMuscle & Nerve, 2008
- Cognitive dysfunction in patients with amyotrophic lateral sclerosis is associated with spherical or crescent-shaped ubiquitinated intraneuronal inclusions in the parahippocampal gyrus and amygdala, but not in the neostriatumActa Neuropathologica, 2001